skip to content »

Department of Psychiatry

Houston, Texas

The Alkek Building at Baylor College of Medicine
Psychiatry
not shown on screen

Psychiatry Faculty Funded Research

Baylor College of Medicine is ranked among the leading medical schools in the country for research funding. The Menninger Department of Psychiatry has contributed to the school’s history of research excellence, as illustrated by the increase in National Institute of Health and private research funding support. Grants to the department more than doubled between 2005 and 2009. During 2010, the department exceeded $6,000,000 in grant funding, with the areas of addictions and mood disorders showing particularly strong growth.

Getting Started in Research

Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Dates: June 1, 2010 - June 1, 2014
Sponsor: Department of Veterans Affairs
PI: Rayan K. Al Jurdi, M.D.
Email: rayan.aljurdi@bcm.edu

Million Veteran Program: A Partnership With Veterans
Dates: June 3, 2011 - June 3, 2016
Sponsor: Department of Veterans Affairs
PI: Rayan K. Al Jurdi, M.D.
Email: rayan.aljurdi@bcm.edu

Texas TBI Model System of TIRR
Dates: Oct. 1, 2012 - Sept. 30, 2017
Sponsor: National Institute on Disability and Rehabilitation Research
Co-I/Medical Director: David B. Arciniegas, M.D.
Email: david.arciniegas@bcm.edu

Sensorimotor Abnormalities in Childhood Onset Psychiatric Disorders
Dates: June 1, 2009 - May 31, 2014
Sponsor: National Institute of Health and National Institute of Mental Health
Co-I: David B. Arciniegas, M.D.
Email: david.arciniegas@bcm.edu

Neurobehavioral Metrics for the Assessment and Treatment of Depression
Dates: July 1, 2010 – Jan. 31, 2015
Sponsor: National Institute of Mental Health
PI: Pearl Chiu, Ph.D.
Email: pchiu@cpu.bcm.edu

Neuroimaging Major Depression and Nicotine Dependence on Axes of Valuation
Dates: June 30, 2010 - Jan. 31, 2015
Sponsor: National Institute of Mental Health
PI: Pearl Chiu, Ph.D.
Email: pchiu@cpu.bcm.edu

Bupropion Plus Varenicline Treatment: Smoking Cessation (Project Two-2-Quit Conducted at MD Anderson Cancer Center)
Dates: 2008 - 2013
Sponsor: National Institute on Drug Abuse and Pfizer Pharmaceutical Co.
PI: Paul M. Cinciripini, Ph.D.
Co-PI: Maher Karam-Hage, M.D.
Email: pcinciri@mdanderson.org and Email: karamhag@bcm.edu

Genomic, Neural, Preclinical Analyses for Smoking Cessation
Dates: April 1, 2011 - March 30, 2014
Sponsor: Helis Medical Research Foundation
Co-PI: John Dani, Ph.D.
Co-PI: Thomas Kosten, M.D.
Co-PI's: M. DeBiasi, PH.D., R. De La Garza, II, Ph.D., D. Nielsen, PH.D.,
R. Salas, Ph.D., S. Scherer, Ph.D.
Email: jdani@bcm.edu and Email: kosten@bcm.edu

The Neurobiological Effects of Narrative on Empathy
Dates: 2011 - 2013
Sponsor: Defense Advanced Research Projects Agency
PI: David Eagleman, Ph.D.
Email: eagleman@bcm.edu

Synesthesia: From Genes to Neural Networks
Dates: 2011 - 2013
Sponsor: Guggenheim Foundation
PI: David Eagleman, Ph.D.
Email: eagleman@bcm.edu

Target Validation Core Rats
Dates: Sept. 27, 2001 - Aug.31, 2016
Sponsor: National Institute on Alcohol Abuse
PI: Therese Kosten, Ph.D.
Email: tkosten@bcm.edu

Human Methamphetamine Vaccine: Translational Avante Garde Award
Dates: Sept. 30, 2011 - Aug. 31, 2016
Sponsor: National Institute on Drug Abuse
PI: Thomas R. Kosten, M.D.
Email: kosten@bcm.edu

Doxazosin and Nepicastat Outpatient Cocaine Trials
Dates: Sept. 1, 2009 - May 31, 2014
Sponsor: National Institute on Drug Abuse
PI: Thomas Kosten, M.D.
Email: kosten@bcm.edu

Stimulant Pharmacotherapy: Noradrenergic Targets
Dates: Sept. 27, 2004 - May 31, 2014
Sponsor: National Institute on Drug Abuse
PI: Thomas Kosten, M.D.
Email: kosten@bcm.edu

Preventing Aggression in Veterans with Dementia
Dates: March 1, 2011 - Feb. 28, 2015
Sponsor: VA Health Science Research & Development
PI: Mark Kunik, M.D.
Co-PI: Melinda Stanley, Ph.D.
Email: mkunik@bcm.edu and Email: mstanley@bcm.edu

Evaluation of the Efficacy of the CRF1 Antagonist GSKL561679 in Women with PTSD
Dates: 2012 - 2014
Sponsor: National Institute of Mental Health
PI: Sanjay J. Mathew, M.D.
Co-PI: Thomas Newton, M.D.
Email: sjmathew@bcm.edu and Email: tnewton@bcm.edu

Blood Biomarkers of Response to Ketamine
Dates: Sept. 5, 2009 - Sept. 15, 2013
Sponsor: National Alliance for the Research of Schizophrenia and Depression
PI: Sanjay J. Mathew, M.D.
Email: sjmathew@bcm.edu

Optimization of IV Ketamine in Treatment-Resistant Depression
Dates: July 23, 2009 - April 30, 2015
Sponsor: National Institute of Mental Health
PI: Sanjay J. Mathew, M.D.
Email: sjmathew@bcm.edu

Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression
Dates: Aug. 1, 2010 - Oct. 4, 2014
Sponsor: National Institute of Mental Health
PI: Sanjay J. Mathew, M.D.
Email: sjmathew@bcm.edu

Investigation of Neurotrophic Factors and Peripheral Biomarkers (scientific supplement to above Riluzole study)
Dates: 2012 - 2013
Sponsor: National Institute of Mental Health
PI: Sanjay J. Mathew, M.D.
Co-PI: Colin Haile, Ph.D.
Email: sjmathew@bcm.edu and Email: Chaile@bcm.edu

Carisbamate Treatment for Alcohol Dependence
Dates: May 1, 2013 - Oct. 31, 2013
Sponsor: National Institute of Health and National Institute on Alcohol Abuse and Alcoholism
PI: Thomas Newton, M.D.
Email: tnewton@bcm.edu

Clinical Research Education for Drug Abuse Professionals
Dates: March 1, 2011 - Feb. 29, 2016
Sponsor: National Institute on Drug Abuse
PI: Thomas Newton, M.D.
Email: tnewton@bcm.edu

Neurorehabilitation: Neurons to Networks Center for Rehabilitation Research
Dates: Aug. 20, 2005 - June 30, 2014
Sponsor: National Institute on Drug Abuse
PI: David A. Nielsen, Ph.D..
Email: nielsen@bcm.edu

CHOICES+: Preconception Approach to Reducing Alcohol and Tobacco-Exposed Pregnancy
Dates: Sept. 30, 2010 - Sept. 29, 2013
Sponsor: UT-Austin & Centers for Disease Control and Prevention
PI: Britta Ostermeyer, M.D.
Email: brittao@bcm.edu

Role of Habenula in Major Depression
Dates: Jan. 15, 2013 - Jan. 14. 2015
Sponsor: National Alliance for the Research of Schizophrenia and Depression
PI: Ramiro Salas, Ph.D.
Email: rsalas@bcm.edu

Role of Habenula in Tobacco Addiction
Dates: Aug. 1, 2010 - May 31, 2014
Sponsor: National Institutes of Health
PI: Ramiro Salas, Ph.D.
Email: rsalas@bcm.edu

Investigate the Efficacy and Safety of RO4995819 Versus Placebo, as Adjunctive Therapy in
Patients with Major Depressive Disorder

Dates: Jan, 2012 - Nov, 2013
Sponsor: Roche
PI: Asim Shah, M.D.
Email: aashah@bcm.edu
Co-PI: Sanjay Mathew, M.D.
Email: sjmathew@bcm.edu
Co-PI: Britta Ostermeyer, M.D.
Email: brittao@bcm.edu

Family Psychoeducation for Iraq and Afghanistan Wars Veterans with Post Traumatic Stress Disorder
Dates: Aug. 23, 2012 - Apr. 16, 2014
Sponsor: Suicide Prevention Initiatives
PI: Bengi Melton, M.D.
Coordinator: Christine Jacobsen, M.A., M.Ed
Emails: bbmelton@bcm.edu and Email: jacobsen@bcm.edu

CBT for Late-Life GAD in Primary Care: Enhancing Outcomes and Translational Value
Dates: Sept. 1, 1996 - April 30, 2014
Sponsor: National Institute on Mental Health
PI: Melinda Stanley, Ph.D.
Email: mstanley@bcm.edu

Maternal Brain and Behavioral Responses to Infant Cues in Cocaine Exposed Mothers
Dates: April 15, 2010 - Jan. 31, 2015
Sponsor: National Institute on Drug Abuse
PI: Lane Strathearn, M.D., Ph.D.
Email: lanes@bcm.edu

Intranasal Oxytocin: A Neuropharmacological Intervention for Maternal Neglect?
Dates: July 1, 2010 - June 30, 2015
Sponsor: National Institute of Health
PI: Lane Strathearn, M.D., Ph.D.
Email: lanes@bcm.edu

Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Adolescents and Adults with Fragile X Syndrome
Dates: 2012 -
Sponsor: Seaside
PI: Diane Treadwell-Deering, M.D.
Email: dianet@bcm.edu

Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Children with Fragile X Syndrome
Dates: 2012 -
Sponsor: Seaside
PI: Diane Treadwell-Deering, M.D.
Email: dianet@bcm.edu

Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 (Arbaclofen) in Subjects with Fragile X Syndrome
Dates: 2012 -
Sponsor: Seaside
PI: Diane Treadwell-Deering, M.D.
Email: dianet@bcm.edu

Safety and Exploratory Efficacy and Pharmacokinetic, Study of RO4917523 in Pediatric Patients with Fragile X Syndrome
Dates: 2012 -
Sponsor: Roche
PI: Diane Treadwell-Deering, M.D.
Email: dianet@bcm.edu

Efficacy and Safety of RO4917523 in Patients with Fragile X Syndrome
Dates: 2012 -
Sponsor: Roche
PI: Diane Treadwell-Deering, M.D.
Email: dianet@bcm.edu

Evaluate the Efficacy and Safety of AFQ056 in Adolescent Patients with Fragile X Syndrome
Dates: 2012 -
Sponsor: Novartis
PI: Diane Treadwell-Deering, M.D.
Email: dianet@bcm.edu

Evaluate AFQ056 in Adult Patients with Fragile X Syndrome
Dates: 2012 -
Sponsor: Novartis
PI: Diane Treadwell-Deering
Email: dianet@bcm.edu

Neuroimaging the Impact of Treatment on Neural Substrates of Trust in PTSD
Dates: Jan. 1, 2011 - Sept. 30, 2013
Sponsor: VA Rehabilitation Research and Development
PI: Wright Williams, Ph.D.
Email: wright.williams@va.gov

E-mail this page to a friend